Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
Clinical trial NCT02564263 · COMPLETED
Trial details
- NCT number
- NCT02564263
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-01
- Primary completion
- 2018-10-15
- Enrollment
- 628
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.